$14.68
3.09% yesterday
Nasdaq, Jun 06, 10:00 pm CET
ISIN
US92790C1045
Symbol
VRDN
Sector
Industry

Viridian Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Viridian Therapeutics Inc Classifications & Recommendation:

Buy
88%
Hold
12%

Viridian Therapeutics Inc Price Target

Target Price $38.31
Price $14.68
Potential
Number of Estimates 16
16 Analysts have issued a price target Viridian Therapeutics Inc 2026 . The average Viridian Therapeutics Inc target price is $38.31. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 15 Analysts recommend Viridian Therapeutics Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Viridian Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Viridian Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 0.30 0.20
3.23% 34.50%
EBITDA Margin -99,513.33% -167,859.80%
21.48% 68.68%
Net Margin -89,983.33% -172,979.10%
17.34% 92.23%

14 Analysts have issued a sales forecast Viridian Therapeutics Inc 2025 . The average Viridian Therapeutics Inc sales estimate is

$197k
Unlock
. This is
34.50% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$822k 174.00%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $300k 3.23%
2025
$197k 34.50%
Unlock
2026
$42.6m 21,587.74%
Unlock
2027
$242m 468.87%
Unlock
2028
$621m 156.16%
Unlock
2029
$993m 59.83%
Unlock

2 Analysts have issued an Viridian Therapeutics Inc EBITDA forecast 2025. The average Viridian Therapeutics Inc EBITDA estimate is

$-330m
Unlock
. This is
1.97% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-320m 4.86%
Unlock
, the lowest is
$-340m 0.91%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-299m 17.56%
2025
$-330m 10.49%
Unlock
2026
$-317m 3.90%
Unlock
2027
$-176m 44.58%
Unlock
2028
$682m 488.05%
Unlock
2029
$1.1b 55.13%
Unlock

EBITDA Margin

2024 -99,513.33% 21.48%
2025
-167,859.80% 68.68%
Unlock
2026
-743.82% 99.56%
Unlock
2027
-72.46% 90.26%
Unlock
2028
109.77% 251.49%
Unlock
2029
106.53% 2.95%
Unlock

5 Viridian Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Viridian Therapeutics Inc net profit estimate is

$-340m
Unlock
. This is
10.24% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-265m 14.00%
Unlock
, the lowest is
$-375m 21.73%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-270m 13.55%
2025
$-340m 25.91%
Unlock
2026
$-329m 3.22%
Unlock
2027
$-106m 67.67%
Unlock
2028
$175m 264.44%
Unlock
2029
$384m 119.44%
Unlock

Net Margin

2024 -89,983.33% 17.34%
2025
-172,979.10% 92.23%
Unlock
2026
-771.93% 99.55%
Unlock
2027
-43.86% 94.32%
Unlock
2028
28.16% 164.20%
Unlock
2029
38.66% 37.29%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.98 -4.17
25.05% 4.77%
P/E negative
EV/Sales 2,960.92

5 Analysts have issued a Viridian Therapeutics Inc forecast for earnings per share. The average Viridian Therapeutics Inc EPS is

$-4.17
Unlock
. This is
10.03% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.25 14.25%
Unlock
, the lowest is
$-4.60 21.37%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.98 25.05%
2025
$-4.17 4.77%
Unlock
2026
$-4.03 3.36%
Unlock
2027
$-1.30 67.74%
Unlock
2028
$2.14 264.62%
Unlock
2029
$4.70 119.63%
Unlock

P/E ratio

Current -3.87 15.39%
2025
-3.52 9.12%
Unlock
2026
-3.64 3.41%
Unlock
2027
-11.26 209.34%
Unlock
2028
6.85 160.83%
Unlock
2029
3.12 54.45%
Unlock

Based on analysts' sales estimates for 2025, the Viridian Therapeutics Inc stock is valued at an EV/Sales of

2,960.92
Unlock
and an P/S ratio of
6,095.52
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1,939.40 219.77%
2025
2,960.92 52.67%
Unlock
2026
13.65 99.54%
Unlock
2027
2.40 82.42%
Unlock
2028
0.94 60.96%
Unlock
2029
0.59 37.43%
Unlock

P/S ratio

Current 3,992.57 46.58%
2025
6,095.52 52.67%
Unlock
2026
28.11 99.54%
Unlock
2027
4.94 82.42%
Unlock
2028
1.93 60.96%
Unlock
2029
1.21 37.43%
Unlock

Current Viridian Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Needham
Locked
Locked
Locked May 20 2025
JMP Securities
Locked
Locked
Locked May 07 2025
Goldman Sachs
Locked
Locked
Locked May 07 2025
Needham
Locked
Locked
Locked May 07 2025
RBC Capital
Locked
Locked
Locked May 07 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 23 2025
Needham
Locked
Locked
Locked Jan 07 2025
Analyst Rating Date
Locked
Needham:
Locked
Locked
May 20 2025
Locked
JMP Securities:
Locked
Locked
May 07 2025
Locked
Goldman Sachs:
Locked
Locked
May 07 2025
Locked
Needham:
Locked
Locked
May 07 2025
Locked
RBC Capital:
Locked
Locked
May 07 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 23 2025
Locked
Needham:
Locked
Locked
Jan 07 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today